Literature DB >> 11176941

High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.

V I Leussink1, S Jung, U Merschdorf, K V Toyka, R Gold.   

Abstract

BACKGROUND: Apoptosis is supposed to contribute to the elimination of T cells from the inflamed central nervous system in the natural disease course of multiple sclerosis (MS). In the animal model experimental autoimmune encephalomyelitis, T-cell apoptosis can be induced by high-dose glucocorticoid (GC) administration.
OBJECTIVE: To study the effects of intravenous high-dose GC therapy in MS on T-cell apoptosis ex vivo. PATIENTS: Sixty-six patients with MS (28 with relapsing-remitting MS, 22 with secondary chronic progressive MS, and 16 with primary chronic progressive MS) and 16 control patients receiving corticosteroids for other disorders were included in the study.
METHODS: Blood samples were collected before and immediately after the first infusion of 500 to 1000 mg of methylprednisolone given during 2 hours in the early morning. Gradient-isolated peripheral blood leukocytes (PBLs) were cultured, unstimulated, with corticosteroids (positive control), the mitogen phytohemagglutinin, or anti-T-cell receptor monoclonal antibody. For investigation of apoptosis, PBLs were cultured overnight and analyzed by immunoflow cytometry using TUNEL (terminal transferase-mediated dUTP biotin nick end labeling) or annexin labeling in combination with CD4, CD8, CD22, CD56, or bcl-2 staining. Proliferation was measured by (3)H-thymidine incorporation. For cytokine determination, supernatants were collected after 48 hours of culture.
RESULTS: After in vivo corticosteroid treatment, apoptosis of unstimulated PBLs was markedly and significantly augmented in all 3 MS subgroups. Fluorescence-activated cell sorter analysis showed that apoptosis affected predominantly CD4 T cells. Natural killer cells showed a relative increase after GC therapy without a change in the rate of apoptotic cells. Expression of bcl-2 in T-cell subpopulations was not significantly modified by high-dose GC therapy. Culture supernatants of T-cell receptor-stimulated PBLs after GC therapy contained lower concentrations of interleukin 2, interferon gamma, and tumor necrosis factor alpha than those from PBLs taken before pulse therapy. Similar changes in the rate of apoptosis and cytokine production were seen in controls.
CONCLUSIONS: Corticosteroid pulse therapy is a strong inducer of leukocyte apoptosis. Induction of apoptosis might contribute to the down-regulation of T-cell activity and thereby terminate inflammation in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176941     DOI: 10.1001/archneur.58.1.91

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  25 in total

1.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

2.  Corticosteroids in the treatment of alcohol-induced rhabdomyolysis.

Authors:  James W Antoon; Chayan Chakraborti
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Authors:  A Chan; F X Weilbach; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

5.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Authors:  Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney
Journal:  Neuro Oncol       Date:  2009-12-22       Impact factor: 12.300

Review 6.  Thalamus pathology in multiple sclerosis: from biology to clinical application.

Authors:  Markus Kipp; Nina Wagenknecht; Cordian Beyer; Sebastian Samer; Jens Wuerfel; Omid Nikoubashman
Journal:  Cell Mol Life Sci       Date:  2014-11-23       Impact factor: 9.261

7.  Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.

Authors:  Bartosz Bielecki; Andzelika Mazurek; Paweł Wolinski; Andrzej Glabinski
Journal:  J Clin Immunol       Date:  2007-10-25       Impact factor: 8.317

8.  Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

Authors:  M Braitch; S Harikrishnan; R A Robins; C Nichols; A J Fahey; L Showe; C S Constantinescu
Journal:  Acta Neurol Scand       Date:  2009-04       Impact factor: 3.209

9.  Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity.

Authors:  F Kamin; P S Rommer; M Abu-Mugheisib; W Koehler; F Hoffmann; A Winkelmann; R Benecke; U K Zettl
Journal:  Spinal Cord       Date:  2014-09-16       Impact factor: 2.772

10.  Garlic compounds selectively kill childhood pre-B acute lymphoblastic leukemia cells in vitro without reducing T-cell function: Potential therapeutic use in the treatment of ALL.

Authors:  Greg Hodge; Stephen Davis; Michael Rice; Heather Tapp; Ben Saxon; Tamas Revesz
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.